| PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. We show 31 historical shares outstanding datapoints in our PTCT shares outstanding history coverage, used to compute PTCT market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PTCT market cap history over the course of time is important for investors
interested in comparing PTCT's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PTCT versus a peer is one thing; comparing
PTCT market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PTCT can fluctuate over the course of history.
With this page we aim to empower investors researching PTCT by allowing them to research the PTCT market cap history.